On January 10, 2020, the Board of Directors of EyeGate Pharmaceuticals, Inc. upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Keith Maher, M.D. as a Class III director of the company to fill the vacancy created by the previously disclosed resignation of Peter Greenleaf as a member of the Board. Dr. Maher’s appointment was effective as of January 10, 2020, and he will serve in office until the 2021 annual meeting of stockholders or until his successor is duly elected and qualified or until his earlier resignation or removal. Keith Maher, M.D. has worked at Armistice Capital covering healthcare since 2019. From 2013 through 2018, Dr. Maher served as the North American healthcare analyst for Schroder Investment Management. Prior to joining Schroder, Dr. Maher held senior roles at Omega Advisors, Gracie Capital and Paramount BioCapital. Prior to joining Paramount, Dr. Maher was a Managing Director at Weiss, Peck & Greer (WPG) Investments. He joined WPG from Lehman Brothers, where he worked as an equity research analyst covering medical device and technology companies. Dr. Maher has served on the board of directors of Vaxart, Inc., a Nasdaq-listed clinical stage company developing tablet vaccines, since November 2019.